ALLMedicine™ Acute Graft Versus Host Disease Center
Research & Reviews 97 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389423
PloS One; Kreft A, Hippe K et. al.
Aug 27th, 2021 - Acute graft versus host disease (aGvHD) is an important, life-threatening complication after allogeneic hematopoietic stem cell transplantation (alloHSCT). To investigate the value of multiple simultaneous colon biopsies in improving diagnostic ac...
https://doi.org/10.1016/j.retram.2021.103307
Current Research in Translational Medicine; Jafari L, Izadirad M et. al.
Aug 12th, 2021 - Acute graft versus host disease (aGVHD) is an immune-mediated reaction that results in impaired immune and body function after allogeneic hematopoietic stem cell transplantation (allo-HSCT). lncRNAs have been discovered as particular T cell regula...
https://doi.org/10.1038/s41409-021-01386-8 10.1182/blood-2010-01-261958 10.1200/JCO.2004.02.189 10.1038/bmt.2010.174 10.1056/NEJMra1609337 10.1182/bloodadvances.2017011502 10.1016/S0140-6736(09)60237-3 10.1155/2012/257086 10.1182/blood-2016-09-737700 10.1097/TP.0b013e3182708e7c 10.18632/oncotarget.20310 10.1016/j.bbmt.2019.11.026 10.1182/blood-2015-09-669846 10.1038/nature15393 10.1038/nprot.2009.86 10.1086/519795 10.1038/bmt.2012.244 10.1006/abio.1999.4293 10.2174/1389200215666140202214012 10.1182/blood-2017-11-817973 10.1038/sigtrans.2017.23 10.1111/bjh.13959 10.1126/science.1098387 10.1038/nature08467 10.1007/s00277-020-03935-5 10.1007/s10549-015-3368-5 10.1002/humu.21641 10.1111/ahg.12293 10.1093/brain/awu408 10.1038/srep18475 10.4049/jimmunol.179.1.647 10.3389/fimmu.2012.00118 10.1038/nature24277 10.1038/onc.2013.587 10.1038/leu.2013.206 10.1161/CIRCULATIONAHA.113.001720 10.1016/j.beha.2008.02.003 10.1016/j.beha.2008.02.002 10.1111/bjh.15456 10.1038/nri2327 10.1182/blood-2013-08-519157 10.1111/j.1365-2443.2011.01529.x 10.4049/jimmunol.1500531 10.1182/blood-2013-11-536888 10.1261/rna.747607 10.1261/rna.075416.120 10.1111/gbb.12127 10.1111/iji.12051 10.1046/j.1365-2141.2003.04676.x 10.1128/MCB.00480-14
Bone Marrow Transplantation; Ansari M, Petrykey K et. al.
Jul 4th, 2021 - The most frequent complication of allogeneic hematopoietic stem cell transplantation is acute Graft versus Host Disease (aGVHD). Proliferation and differentiation of donor T cells initiate inflammatory response affecting the skin, liver, and gastr...
https://doi.org/10.1038/s41375-021-01312-3 10.1182/blood-2010-08-302109 10.1182/blood.V98.7.2043 10.1126/science.273.5271.70 10.1038/nm.3733 10.1056/NEJMoa1408617 10.1056/NEJMoa1409405 10.1182/blood-2015-03-631747 10.1093/eurheartj/ehz591 10.1056/NEJMoa1701719 10.1126/science.aag1381 10.1200/JCO.2018.79.2184 10.1200/JCO.2017.77.6757 10.1016/j.plipres.2011.04.002 10.1038/ni.3464 10.1073/pnas.1616420114 10.1182/blood-2014-01-514786 10.1084/jem.20130084
Leukemia Oran B, Champlin RE et. al.
Jun 18th, 2021 - Clonal hematopoiesis (CH) is associated with older age and an increased risk of myeloid malignancies and cardiovascular complications. We analyzed donor DNA samples in patients with AML/MDS who underwent first allogeneic stem cell transplant (SCT)...
https://doi.org/10.1111/petr.14041
Pediatric Transplantation; Wright M, Rangarajan H et. al.
May 21st, 2021 - Immunosuppressive prophylaxis is usually given to decrease the development of acute graft versus host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Belatacept is a Cytotoxic T-lymphocyte-associated protein 4, bloc...
News 4 results
https://www.onclive.com/view/genomic-era-reaches-pediatric-oncology
Dec 5th, 2020 - Rajen Mody, MBBS The relative rarity of pediatric cancers has hampered the work of uncovering their causes and developing new therapies, but efforts to expand the use of genomic and biomarker testing are beginning to provide new options for child...
https://www.onclive.com/view/fda-sets-review-date-for-remestemcel-l-for-steroid-refractory-pediatric-acute-gvhd
Jul 21st, 2020 - The FDA’s Oncologic Drugs Advisory Committee (ODAC) has scheduled a date to review data supporting the biologics license application (BLA) for remestemcel-L (Ryoncil) as a treatment for children with steroid-refractory acute graft versus host dise...
https://www.medpagetoday.com/primarycare/generalprimarycare/80082
May 28th, 2019 - Note that some links may require subscriptions. Teva Pharmaceuticals agreed to an $85 million settlement with Oklahoma over an alleged role in the state's opioid crisis -- which the company denied. (CNN) Incyte announced the FDA expanded indicatio...
https://www.reuters.com/article/us-mesoblast-study/mesoblast-stem-cell-therapy-meets-goal-of-pediatric-graft-vs-host-study-idUSKCN1G52W2
Feb 21st, 2018 - (Reuters) - Nearly 70 percent of children with potentially fatal acute Graft Versus Host Disease responded to treatment with an experimental stem cell therapy from Mesoblast Ltd, meeting the primary goal of a late-stage U.S. trial, the Australian ...
